Zarontin
Zarontin® (Ethosuximide Capsules, USP)
Approved
Approval ID
0e008f33-70a1-4bc6-b3a0-d45214418ab6
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Jun 8, 2023
Manufacturers
FDA
Parke-Davis Div of Pfizer Inc
DUNS: 829076962
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Ethosuximide
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code0071-0237
Application NumberNDA012380
Product Classification
M
Marketing Category
C73594
G
Generic Name
Ethosuximide
Product Specifications
Route of AdministrationORAL
Effective DateJune 8, 2023
FDA Product Classification
INGREDIENTS (7)
ETHOSUXIMIDEActive
Quantity: 250 mg in 1 1
Code: 5SEH9X1D1D
Classification: ACTIB
POLYETHYLENE GLYCOL 400Inactive
Code: B697894SGQ
Classification: IACT
D&C YELLOW NO. 10Inactive
Code: 35SW5USQ3G
Classification: IACT
FD&C RED NO. 3Inactive
Code: PN2ZH5LOQY
Classification: IACT
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT
SORBITOLInactive
Code: 506T60A25R
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT